[go: up one dir, main page]

MA57908B1 - Composés macrocycliques substitués et méthodes de traitement associées - Google Patents

Composés macrocycliques substitués et méthodes de traitement associées

Info

Publication number
MA57908B1
MA57908B1 MA57908A MA57908A MA57908B1 MA 57908 B1 MA57908 B1 MA 57908B1 MA 57908 A MA57908 A MA 57908A MA 57908 A MA57908 A MA 57908A MA 57908 B1 MA57908 B1 MA 57908B1
Authority
MA
Morocco
Prior art keywords
methods
processing
macrocyclic compounds
substituted macrocyclic
substituted
Prior art date
Application number
MA57908A
Other languages
English (en)
Inventor
Lewis D. Pennington
Younggi Choi
Hoan Huynh
Brian M. Aquila
Ingo Mugge
Yuan HU
James R. Woods
Roman A. Valiulin
Brian Kenneth Raymer
Jorg Martin BENTZIEN
Michael R. Hale
Jonathan Ward LEHMANN
Daljit MATHARU
Srinivasa Karra
Original Assignee
Alkermes, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes, Inc. filed Critical Alkermes, Inc.
Publication of MA57908B1 publication Critical patent/MA57908B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés (I) et (II) utiles pour le traitement de la narcolepsie ou de la cataplexie chez un sujet qui le nécessite. L'invention concerne également des compositions pharmaceutiques et des méthodes associées.
MA57908A 2019-11-25 2020-11-25 Composés macrocycliques substitués et méthodes de traitement associées MA57908B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962939825P 2019-11-25 2019-11-25
US202063030979P 2020-05-28 2020-05-28
EP20828463.8A EP4065585B1 (fr) 2019-11-25 2020-11-25 Composés macrocycliques substitués et méthodes de traitement associées
PCT/US2020/062320 WO2021108628A1 (fr) 2019-11-25 2020-11-25 Composés macrocycliques substitués et méthodes de traitement associées

Publications (1)

Publication Number Publication Date
MA57908B1 true MA57908B1 (fr) 2025-09-30

Family

ID=73856348

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57908A MA57908B1 (fr) 2019-11-25 2020-11-25 Composés macrocycliques substitués et méthodes de traitement associées

Country Status (24)

Country Link
US (3) US11542276B2 (fr)
EP (2) EP4628167A3 (fr)
JP (1) JP7787812B2 (fr)
KR (1) KR20220106793A (fr)
CN (1) CN114761412B (fr)
AU (2) AU2020394444B2 (fr)
BR (1) BR112022009938A2 (fr)
CA (1) CA3155885A1 (fr)
DK (1) DK4065585T3 (fr)
ES (1) ES3041424T3 (fr)
FI (1) FI4065585T3 (fr)
HR (1) HRP20251156T1 (fr)
IL (2) IL320038A (fr)
LT (1) LT4065585T (fr)
MA (1) MA57908B1 (fr)
MX (1) MX2022006206A (fr)
NZ (1) NZ787541A (fr)
PT (1) PT4065585T (fr)
RS (1) RS67202B1 (fr)
SA (1) SA522432691B1 (fr)
SI (1) SI4065585T1 (fr)
SM (1) SMT202500340T1 (fr)
WO (1) WO2021108628A1 (fr)
ZA (1) ZA202206482B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ787541A (en) 2019-11-25 2025-10-31 Alkermes Inc Substituted macrocyclic compounds and related methods of treatment
US20230331720A1 (en) * 2020-09-03 2023-10-19 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
EP4247801A4 (fr) * 2020-11-23 2024-10-30 Merck Sharp & Dohme LLC Agonistes du récepteur de l'orexine de type 3-amino pyrrolidine et pipéridine macrocyclique
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP2024516633A (ja) * 2021-04-26 2024-04-16 アルカーメス，インコーポレイテッド オレキシン－２受容体アゴニスト活性を有する置換されるアミド大環状化合物
AU2022281345A1 (en) * 2021-05-26 2023-11-30 Alkermes, Inc. Substituted fused bicyclic macrocyclic compounds and related methods of treatment
CA3219490A1 (fr) * 2021-05-26 2022-12-01 Alkermes, Inc. Composes macrocycliques de carbamate substitues et methodes de traitement associees
WO2023167925A1 (fr) * 2022-03-01 2023-09-07 Orexia Therapeutics Limited Dérivés hétérocycliques à substitution benzyle moyenne ou macro-cyclique et utilisations associées
EP4611745A1 (fr) * 2022-10-31 2025-09-10 Takeda Pharmaceutical Company Limited Dosage d'agonistes du récepteur de type 2 de l'orexine
WO2024112899A1 (fr) * 2022-11-23 2024-05-30 Vertex Pharmaceuticals Incorporated Modulateurs d'amine macrocycliques substitués du récepteur 2 de l'orexine
AU2023395547A1 (en) 2022-12-16 2025-06-26 Daiichi Sankyo Company, Limited 2-azabicyclo[3.1.1]heptane compound
IL322460A (en) 2023-01-31 2025-09-01 Jazz Pharmaceuticals Ireland Ltd Macrocyclic orexin receptor agonists and uses thereof
KR20250155550A (ko) 2023-03-16 2025-10-30 다케다 야쿠힌 고교 가부시키가이샤 매크로시클릭 헤테로시클 화합물 및 이의 용도
TW202448426A (zh) 2023-06-01 2024-12-16 丹麥商Ｈ 朗德貝克公司 大螺環食欲素2受體促效劑
TW202502342A (zh) 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途
WO2025085740A1 (fr) * 2023-10-20 2025-04-24 Alkermes, Inc. Composé destiné à être utilisé dans le traitement de la narcolepsie
WO2025096445A1 (fr) 2023-10-30 2025-05-08 Alkermes, Inc. Synthèse d'intermédiaires pour la préparation de composés macrocycliques
WO2025124698A1 (fr) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Dérivés d'arylsulfone et de sulfanone utilisés en tant que modulateurs du récepteur de l'orexine
WO2025132542A1 (fr) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Agonistes macrocycliques de l'orexine
WO2025211416A1 (fr) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 Composé macrocyclique de sulfonamide substitué
WO2025224168A1 (fr) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Dérivés d'arylsulfone et de sulfanone utilisés en tant que modulateurs du récepteur de l'orexine
WO2025229493A1 (fr) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosage d'agonistes du récepteur de l'orexine de type 2

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
DE69835828T2 (de) 1997-10-31 2007-04-12 Biomira, Inc., Edmonton Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
WO1999046392A1 (fr) 1998-03-12 1999-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methodes et compositions utilisant des proteines de fusion chemokine-antigene tumoral comme vaccins anti-cancer
US6492492B1 (en) 1998-04-03 2002-12-10 University Of Washington Circularly permuted biotin binding proteins
JP2002530066A (ja) 1998-11-19 2002-09-17 スミスクライン・ビーチャム・コーポレイション Ｒｈａｍｍアンタゴニスト抗体
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
JP4944324B2 (ja) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2001231532A1 (en) 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
AU2001256981A1 (en) 2000-04-06 2001-10-23 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
EP1355942B1 (fr) 2000-12-07 2008-08-27 Eli Lilly And Company Proteines hybrides glp-1
CN1549723A (zh) 2001-02-06 2004-11-24 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰白介素-1受体拮抗剂(il-1ra)
CA2454469A1 (fr) 2001-07-20 2003-02-06 Absorber, Ab Complexes polypeptides de fusion/antigenes des groupes sanguins, et procedes d'utilisation
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
NZ538629A (en) 2002-08-09 2008-05-30 Recopharma Ab Mucin-immunoglobulin fusion proteins
AU2003280315A1 (en) 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
PL378879A1 (pl) 2002-12-30 2006-05-29 Amgen Inc. Terapia skojarzona z czynnikami kostymulującymi
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2005034863A2 (fr) 2003-10-03 2005-04-21 Jarikuma Corporation Mesures contre le paludisme
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
CA2583983C (fr) 2004-10-14 2013-07-16 Abbott Gmbh & Co. Kg Composes heterocycliques convenant pour traiter des troubles sensibles a une modulation du recepteur d3 de la dopamine
CN101132800A (zh) 2004-11-24 2008-02-27 席拉坎有限责任公司 一种用于眼内药物释出的植入体
AU2006216651A1 (en) 2005-02-23 2006-08-31 Prexa Pharmaceuticals, Inc. Multimediator dopamine transport inhibitors, and uses related thereto
CA2618791C (fr) 2005-08-12 2014-05-13 Riken Nouvelle glycoproteine de type mucine et applications
JPWO2007063907A1 (ja) 2005-11-30 2009-05-07 塩野義製薬株式会社 ペプチド糖鎖付加体およびそれを有効成分とする医薬
DE602005015733D1 (de) 2005-12-02 2009-09-10 Apceth Gmbh & Co Kg Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration
WO2008140595A2 (fr) 2006-12-01 2008-11-20 President And Fellows Of Harvard College Haptènes trivalents synthétiques, complexes de ceux-ci et utilisations de ceux-ci
WO2008133928A2 (fr) 2007-04-27 2008-11-06 The Gi Company, Inc. Utilisation de glycoprotéines mucines en combinaison avec des agents thérapeutiques pour traiter les lésions épithéliales et les troubles d'altération de la fonction de la mucine
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
BRPI0914889A2 (pt) 2008-06-17 2015-11-24 Otsuka Chemical Co Ltd peptídeo glp-1 adicionado de cadeia oligossacarídica
EP2331554B1 (fr) * 2008-08-14 2013-03-06 Janssen R&D Ireland Dérivés d'indoles macrocycliques en tant qu'inhibiteurs du virus de l'hépatite c
JP2012525415A (ja) 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
MY165918A (en) 2009-06-26 2018-05-18 Pfizer Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
CA2785139A1 (fr) 2009-12-22 2011-06-30 Novartis Ag Proteine hybride tetravalente a region constante d'anticorps anti-cd-47 a utiliser en therapie
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
CN101962413B (zh) 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
EP2457579A1 (fr) 2010-11-26 2012-05-30 Technische Universität Dresden Interleukine 10 à liaison covalente
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2694472B1 (fr) 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Dérivé de sulfonamide et son utilisation
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2723380B1 (fr) 2011-06-24 2019-08-21 Stephen D. Gillies Protéines hybrides d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
ES2857734T3 (es) 2011-08-23 2021-09-29 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
WO2013139697A1 (fr) 2012-03-17 2013-09-26 Polyphor Ag Composés macrocycliques entièrement synthétiques et à conformation contrainte
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
WO2013170636A1 (fr) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 Protéine et conjugué protéique pour le traitement du diabète et applications associées
WO2013184938A2 (fr) 2012-06-08 2013-12-12 Alkermes. Inc. Polypeptides de fusion comprenant des lieurs polypeptides à domaine mucin
WO2014018572A2 (fr) 2012-07-23 2014-01-30 Zymeworks Inc. Constructions d'immunoglobuline comprenant un appariement sélectif des chaînes légère et lourde
KR20150038012A (ko) 2012-08-08 2015-04-08 로슈 글리카트 아게 인터루킨-10 융합 단백질 및 그의 용도
CA2903258C (fr) 2013-03-15 2019-11-26 Amgen Inc. Anticorps heterodimeres bispecifiques
US20160068583A1 (en) 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
WO2014198880A1 (fr) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. Composés 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-diones ayant une activité agoniste des récepteurs des orexines de type 2
BR112016002219A2 (pt) 2013-07-31 2017-09-12 Amgen Inc estabilização de polipeptídeos contendo fc
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (fr) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Procédés de traitement d'une insuffisance cardiaque avec des agonistes de récepteur 2 d'hypocrétine
CA2933147A1 (fr) 2013-12-12 2015-06-18 University Of Tsukuba Derive de sulfamide ou son sel d'addition acide pharmaceutiquement acceptable
MX2016010174A (es) 2014-02-06 2016-11-15 Hoffmann La Roche Proteinas de fusion de interleucina-10 y usos de las mismas.
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
MX2017003254A (es) 2014-09-11 2017-10-12 Janssen Pharmaceutica Nv 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
US20160175458A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
WO2016101119A1 (fr) * 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Dérivés d'hétéroaryles fusionnés en tant qu'antagonistes des récepteurs des oréxines
WO2016133160A1 (fr) 2015-02-19 2016-08-25 国立大学法人筑波大学 Dérivé de sulfamide ou sel d'addition d'acide pharmaceutiquement acceptable correspondant
WO2016199906A1 (fr) 2015-06-12 2016-12-15 国立大学法人筑波大学 Dérivé de sulfonamide et sel d'addition d'acide pharmaceutiquement acceptable de celui-ci
HUE051898T2 (hu) * 2015-06-17 2021-03-29 Pfizer Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
AU2016311426B2 (en) * 2015-08-26 2021-05-20 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
BR112018012292A2 (pt) * 2015-12-18 2018-11-27 Novartis Ag compostos e composições tricíclicos como inibidores de cinase
US10508083B2 (en) 2016-02-04 2019-12-17 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
JP7084881B2 (ja) 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
EP3594202B1 (fr) 2017-03-08 2021-08-11 Takeda Pharmaceutical Company Limited Composé de pyrrolidine substituée et son utilisation
EP3594203B1 (fr) 2017-03-08 2021-08-04 Takeda Pharmaceutical Company Limited Composé de pyrrolidine substituée et son utilisation
JP6574918B1 (ja) 2017-08-03 2019-09-11 武田薬品工業株式会社 複素環化合物およびその用途
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
EP3668864B1 (fr) 2017-09-28 2021-07-21 Boehringer Ingelheim International GmbH N-(2,2-difluoroéthyl)-n-[(pyrimidinylamino) propanyle]arylcarboxamides
EP3725780B1 (fr) 2017-12-12 2023-03-01 University of Tsukuba Dérivé de sulfonamide ou sel d'addition d'acide pharmaceutiquement acceptable
MX2020010155A (es) 2018-03-27 2021-03-25 Univ Texas Compuestos de ox2r.
WO2020004537A1 (fr) 2018-06-29 2020-01-02 武田薬品工業株式会社 Composé hétérocyclique et son utilisation
EP3816154B1 (fr) 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son application
US12091410B2 (en) 2018-12-12 2024-09-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2020122092A1 (fr) 2018-12-12 2020-06-18 武田薬品工業株式会社 Composé hétérocyclique
EA202192138A1 (ru) 2019-01-31 2022-03-10 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение
EP3924058A1 (fr) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
WO2021026047A1 (fr) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
MX2022003017A (es) 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva.
NZ787541A (en) 2019-11-25 2025-10-31 Alkermes Inc Substituted macrocyclic compounds and related methods of treatment
CA3163200A1 (fr) 2019-11-27 2021-06-03 Takeda Pharmaceutical Company Limited Compose heterocyclique
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
KR20220127245A (ko) 2020-01-10 2022-09-19 다케다 야쿠힌 고교 가부시키가이샤 사이토크롬 p450의 억제제를 사용하여 메틸 3-((메틸술포닐)아미노)-2-(((4-페닐시클로헥실)옥시)메틸)피페리딘-1-카르복실레이트 또는 그의 염의 약동학을 향상시키거나 혈장 농도를 증가시키기 위한 방법
CA3187835A1 (fr) 2020-07-17 2022-01-20 Eisai R&D Management Co., Ltd. Compose de piperidine substitue et son application
US12497362B2 (en) 2020-08-18 2025-12-16 Merck Sharp & Dohme Llc Cyclopentapyrrole orexin receptor agonists
GEAP202416395A (en) 2020-08-18 2024-02-12 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists
US20230331720A1 (en) 2020-09-03 2023-10-19 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
TW202227397A (zh) 2020-09-03 2022-07-16 英商歐瑞夏治療公司 雙環的－雜環衍生物及相關用途
JP2022064180A (ja) 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
WO2022094012A1 (fr) 2020-11-02 2022-05-05 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine d'urée macrocyclique
EP4247801A4 (fr) 2020-11-23 2024-10-30 Merck Sharp & Dohme LLC Agonistes du récepteur de l'orexine de type 3-amino pyrrolidine et pipéridine macrocyclique
EP4255429A4 (fr) 2020-12-03 2024-12-11 Merck Sharp & Dohme LLC Agonistes 3-hétéroaryl pyrrolidine et pipéridine des récepteurs de l'orexine
WO2022132696A1 (fr) 2020-12-16 2022-06-23 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine d'urée
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
CA3208567A1 (fr) 2021-03-03 2022-09-09 Yanan Zhang Arylsulfonamides utilises en tant qu'agonistes du recepteur de l'orexine
WO2022207935A1 (fr) 2021-04-02 2022-10-06 Orexia Therapeutics Limited Dérivés hétérocycliques substitués en 2-(3-éthynylbenzyle) en tant qu'agonistes de l'orexine 2
EP4334323A1 (fr) 2021-05-03 2024-03-13 Jazz Pharmaceuticals Ireland Limited Agonistes du récepteur de l'orexine et leurs utilisations

Also Published As

Publication number Publication date
KR20220106793A (ko) 2022-07-29
LT4065585T (lt) 2025-10-10
US20230339969A1 (en) 2023-10-26
CN114761412B (zh) 2024-10-11
CA3155885A1 (fr) 2021-06-03
SMT202500340T1 (it) 2025-11-10
ZA202206482B (en) 2025-10-29
IL293240B1 (en) 2025-05-01
RS67202B1 (sr) 2025-10-31
US11542276B2 (en) 2023-01-03
CN114761412A (zh) 2022-07-15
DK4065585T3 (da) 2025-09-08
MX2022006206A (es) 2022-09-09
SI4065585T1 (sl) 2025-11-28
EP4065585A1 (fr) 2022-10-05
AU2020394444A1 (en) 2022-05-19
IL293240A (en) 2022-07-01
PT4065585T (pt) 2025-09-30
IL293240B2 (en) 2025-09-01
BR112022009938A2 (pt) 2022-09-13
US20250092063A1 (en) 2025-03-20
EP4065585B1 (fr) 2025-08-20
JP2023502441A (ja) 2023-01-24
AU2020394444B2 (en) 2025-05-29
JP7787812B2 (ja) 2025-12-17
ES3041424T3 (en) 2025-11-12
SA522432691B1 (ar) 2025-05-27
EP4628167A2 (fr) 2025-10-08
IL320038A (en) 2025-06-01
US12054495B2 (en) 2024-08-06
NZ787541A (en) 2025-10-31
EP4628167A3 (fr) 2025-12-03
WO2021108628A1 (fr) 2021-06-03
US20210155636A1 (en) 2021-05-27
FI4065585T3 (fi) 2025-09-26
HRP20251156T1 (hr) 2025-11-21
AU2025203295A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
MA57908B1 (fr) Composés macrocycliques substitués et méthodes de traitement associées
MA51530B1 (fr) Composés cycliques fondus
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA57972B1 (fr) Inhibiteurs de parp1
EP3924481A4 (fr) Compositions et méthodes de traitement d'hémoglobinopathies
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA53937B1 (fr) Compositions comprenant des souches bactériennes
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA54975A1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA52288B1 (fr) Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA50406B1 (fr) Inhibiteurs pyrazole de magl
EP1796669A4 (fr) Aminopiperidines utilisees comme inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MA54386B1 (fr) Modulateurs de trex1
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA34308B1 (fr) Triazolopyridines substituées
MA54133B1 (fr) Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
MA40378B1 (fr) Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de la tétrahydroquinoléine
MA62935B1 (fr) Méthodes de traitement ou de prévention de l'amyotrophie spinale
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
CA3236794A1 (fr) Compositions et methodes pour le traitement de l'epilepsie
EP3810647A4 (fr) Méthodes et compositions pour le traitement de l'hémophilie
EP4069278A4 (fr) Méthodes et compositions pour le traitement et la prévention du diabète de type 1